Atrium Therapeutics, Inc. Common Stock

RNA XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

210M

Short interest (May 15)

24.1%

Net Short (Jun 03 ): 0.0%

Borrow Fee

1.16%

↓ 46.5%

Available Shares

500K

↑ 5.9%

Price Chart

Company Overview

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0002093101

Asset Type: CS

Market Data

Market Cap: $209,544,126

Employees: 391

Status: Active

Short Interest

Current Borrow Fee 1.16%

Range: 0.47% - 1.16%

Available Shares 500K

Range: 250K - 550K

Recent Changes

Fee Change: ↑ 11.2%

Available Change: ↑ 5.3%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime